Controversies regarding screening for prostate cancer

BJU International

Volumn 100, Issue SUPPL. 2, 2007, Pages 5-7

  Crawford, E David ^a,b   Thompson, Ian M ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; COST OF ILLNESS; ERECTILE DYSFUNCTION; HUMAN; INCONTINENCE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34250839510     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06943.x     Document Type: Short Survey

References (21)

1. Crawford ED. Prostate Cancer Awareness Week: September 22-28, 1997. CA Cancer J Clin 1997 47 : 288 96
2. National Cancer Institute. US National Institutes of Health Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) Devcan Database: SEER 17 Incidence and Mortality, 2000-2003, with Kaposi Sarcoma and Mesothelioma. National Cancer Institute, November 2005, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the submission. Underlying mortality data provided by NCHS (http://www.cdc.gov/nchs)
3. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 24
4. Thompson IM. Chemoprevention of prostate cancer: lessons learned. BJU Int 2007 99 : in press
5. Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin 1999 49 : 264 81
6. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family. JAMA 1993 270 : 2444 50
7. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998 90 : 1817 23
8. Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002 168 : 1980 4
9. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46
10. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996 47 : 863 9
11. Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate 1999 38 : 296 302
12. Crawford ED, Schultz MJ, Clejan S et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992 267 : 2227 8
13. DeAntoni EP. Eight years of 'Prostate Cancer Awareness Week': lessons in screening and early detection. Prostate Cancer Education Council. Cancer 1997 80 : 1845 51
14. Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000 21 (Suppl. 273S 309S
15. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993 150 : 379 85
16. Cookson MS. Prostate cancer: screening and early detection. Cancer Control 2001 8 : 133 40
17. Optenberg SA, Thompson IM. Economics of screening for cancer of the prostate. Urol Clin North Am 1990 17 : 719 37
18. Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schroder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998 90 : 925 31
19. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996 275 : 288 94
20. Thompson IM, Optenberg SA. An overview cost-utility analysis of prostate cancer screening. Oncology (Williston Park) 1995 9 (Suppl. 141 5
21. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998 82 : 249 51